Clinical Trial Update: Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

This entry covers a Phase 2 clinical trial evaluating Bipolar Androgen Therapy (BAT) in combination with Radium-223 for metastatic castration-resistant prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Bipolar Androgen Therapy (BAT)
• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING